Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH)

被引:6
作者
Gabuev, A. [1 ]
Oelke, M. [1 ]
机构
[1] Hannover Med Sch, Klin Urol & Urol Onkol, D-30625 Hannover, Germany
关键词
benign prostatic hyperplasia; lower urinary tract symptoms; risk assessment; diagnosis; therapy; URINARY-TRACT SYMPTOMS; BLADDER OUTLET OBSTRUCTION; TITANYL-PHOSPHATE LASER; DETRUSOR WALL THICKNESS; COMMUNITY-DWELLING MEN; COMBINATION THERAPY; FOLLOW-UP; ALPHA(1)-ADRENOCEPTOR ANTAGONISTS; PHOTOSELECTIVE VAPORIZATION; TRANSURETHRAL RESECTION;
D O I
10.1055/s-0031-1271453
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: A re-evaluation of established tests and treatments has become necessary after publication of several new guidelines on BPH during the past two years. This article describes the latest developments concerning epidemiology, diagnosis, and treatment of BPH. Material and Methods: Diagnostic and treatment guidelines on BPH of the German, European, or North American urologists as well as UK doctors were reviewed according to key articles and latest modifications. Results: The only German epidemiological trial on BPH demonstrated that all components of the BPH disease (symptoms prostate enlargement bladder outlet obstruction) increase with ageing. 27% of German men will have disease progression within the next 5 years. Risk factors for disease progression are: age, symptoms, prostate size, PSA, urinary flow rate, and postvoiding residual urine. Diagnosis aims to distinguish BPH from other diseases with similar symptoms, quantify the BPH components, and estimate the individual risk of disease progression. BPH is an exclusion diagnosis. Ultrasonic measurement of detrusor wall thickness at the anterior wall of bladders filled with >= 250 mL can securely detect bladder outlet obstruction if the value is >= 2 mm. Watchful waiting and lifestyle modifications are suitable for men with mild symptoms and low disease progression risk. All drugs used in BPH treatment reduce symptoms but have no influence on bladder outlet obstruction. alpha-blockers are firstline drugs and may be combined with muscarinic receptor antagonists or 5 alpha-reductase inhibitors to further increase efficacy. Prostate surgery is indicated when drug treatment is insufficient, the patient develops complications in the upper or lower urinary tract (absolute indications), or has severe bladder outlet obstruction. Standard operations are TURP in small (<= 80 mL) or open prostatectomy in large prostates (>80 mL). Minimally invasive, alternative surgeries may be considered in selected men and offer advantages with regard to the risk of bleeding, duration of catheterisation, or maintenance of sexual function. Conclusions: Current guidelines have integrated the latest knowledge and developments on BPH and are likely to improve assessment and treatment.
引用
收藏
页码:167 / 178
页数:12
相关论文
共 50 条
  • [1] Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction:: A prospective, randomized, controlled study
    Athanasopoulos, A
    Gyftopoulos, K
    Giannitsas, K
    Fisfis, J
    Perimenis, P
    Barbalias, G
    [J]. JOURNAL OF UROLOGY, 2003, 169 (06) : 2253 - 2256
  • [2] Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
    Barkin, J
    Guimaraes, M
    Jacobi, G
    Pushkar, D
    Taylor, S
    van Vierssen Trip, OB
    [J]. EUROPEAN UROLOGY, 2003, 44 (04) : 461 - 466
  • [3] Berges R, 2008, UROLOGE, V47, P141, DOI 10.1007/s00120-008-1624-6
  • [4] Berges R, 2009, UROLOGE, V48, P1503, DOI 10.1007/s00120-009-2067-4
  • [5] Diagnostics and differential diagnosis of benign prostate syndrome (BPS) Guidelines of the German Urologists
    Berges, R.
    Dreikorn, K.
    Hoefner, K.
    Madersbacher, S.
    Michel, M. C.
    Muschter, R.
    Oelke, M.
    Reich, O.
    Rulf, W.
    Tschuschke, C.
    Tunn, U.
    [J]. UROLOGE, 2009, 48 (11): : 1356 - +
  • [6] Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older
    Berges, Richard
    Oelke, Matthias
    [J]. WORLD JOURNAL OF UROLOGY, 2011, 29 (02) : 171 - 178
  • [7] Male lower urinary tract symptoms and related health care seeking in Germany
    Berges, RR
    Pientka, L
    Höfner, K
    Senge, T
    Jonas, U
    [J]. EUROPEAN UROLOGY, 2001, 39 (06) : 682 - 687
  • [8] THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE
    BERRY, SJ
    COFFEY, DS
    WALSH, PC
    EWING, LL
    [J]. JOURNAL OF UROLOGY, 1984, 132 (03) : 474 - 479
  • [9] A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up
    Bouchier-Hayes, David M.
    Van Appledorn, Scott
    Bugeja, Pat
    Crowe, Helen
    Challacombe, Ben
    Costello, Anthony J.
    [J]. BJU INTERNATIONAL, 2010, 105 (07) : 964 - 969
  • [10] Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
    Boyle, P
    Gould, AL
    Roehrborn, CG
    [J]. UROLOGY, 1996, 48 (03) : 398 - 405